These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 21375607)

  • 1. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma.
    Bueno Angela SP; Viero RM; Soares CT
    Cytopathology; 2013 Feb; 24(1):26-32. PubMed ID: 22220518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
    Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
    Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies.
    Ferguson J; Chamberlain P; Cramer HM; Wu HH
    Diagn Cytopathol; 2013 Jul; 41(7):575-81. PubMed ID: 22807465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
    Satti MB
    Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
    Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
    Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C
    Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.